Bruderman Asset Management’s AVEO Pharmaceuticals, Inc. AVEO Stock Holding History

Bruderman Asset Management’s Portfolio AVEO Stock Details AVEO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-200	Closed	-$2K	–	646
2019 Q1	$2K	Hold	200	–	–	﹤0.01%	588
2018 Q4	$3K	Buy	+200	New	+$4.4K	﹤0.01%	558

Other funds holding AVEO

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Paloma Partners Greenwich, Connecticut $510M AUM 286.05% 1-Year Est. Return

EWM

Evercore Wealth Management New York $6.36B AUM 20.35% 1-Year Est. Return

Bruderman Asset Management's AVEO Position: Q2 2019 in Review

Bruderman Asset Management sold out of AVEO Pharmaceuticals, Inc. (AVEO) in Q2 2019, closing a stake of 200 shares — an estimated $2K sold.

Bruderman Asset Management first reported a position in AVEO in Q4 2018 and held it in 2 quarters. The position peaked at $3K in Q4 2018. 73 funds tracked by Wall St. Rank hold AVEO as of Q2 2019.

Bruderman Asset Management reported no remaining AVEO Pharmaceuticals, Inc. position as of Q2 2019 after selling out during the quarter.
Bruderman Asset Management sold 200 AVEO Pharmaceuticals, Inc. shares in Q2 2019, an estimated $2K.
Bruderman Asset Management first reported a position in AVEO Pharmaceuticals, Inc. in Q4 2018 and held it in 2 quarters.
Bruderman Asset Management's AVEO Pharmaceuticals, Inc. position peaked at $3K in Q4 2018.
73 funds tracked by Wall St. Rank held AVEO Pharmaceuticals, Inc. as of Q2 2019.

Based on Bruderman Asset Management's 13F filing for Q2 2019, filed 12 Aug 2019.